336 related articles for article (PubMed ID: 20303741)
1. Targeting the HGF/Met signalling pathway in cancer.
Cecchi F; Rabe DC; Bottaro DP
Eur J Cancer; 2010 May; 46(7):1260-70. PubMed ID: 20303741
[TBL] [Abstract][Full Text] [Related]
2. Targeting the HGF/Met signaling pathway in cancer therapy.
Cecchi F; Rabe DC; Bottaro DP
Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
[TBL] [Abstract][Full Text] [Related]
3. The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer.
Cecchi F; Rabe DC; Bottaro DP
Curr Signal Transduct Ther; 2011; 6(2):146-151. PubMed ID: 25197268
[TBL] [Abstract][Full Text] [Related]
4. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
5. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
Yap TA; Sandhu SK; Alam SM; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
[TBL] [Abstract][Full Text] [Related]
6. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas.
Mahtouk K; Tjin EP; Spaargaren M; Pals ST
Biochim Biophys Acta; 2010 Dec; 1806(2):208-19. PubMed ID: 20655987
[TBL] [Abstract][Full Text] [Related]
7. The emerging role of MET/HGF inhibitors in oncology.
Scagliotti GV; Novello S; von Pawel J
Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HGF/MET as therapy for malignancy.
Naran S; Zhang X; Hughes SJ
Expert Opin Ther Targets; 2009 May; 13(5):569-81. PubMed ID: 19397476
[TBL] [Abstract][Full Text] [Related]
9. Targeting the c-Met signaling pathway in cancer.
Peruzzi B; Bottaro DP
Clin Cancer Res; 2006 Jun; 12(12):3657-60. PubMed ID: 16778093
[TBL] [Abstract][Full Text] [Related]
10. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
12. Showering c-MET-dependent cancers with drugs.
Knudsen BS; Vande Woude G
Curr Opin Genet Dev; 2008 Feb; 18(1):87-96. PubMed ID: 18406132
[TBL] [Abstract][Full Text] [Related]
13. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
Michieli P; Basilico C; Pennacchietti S; Maffè A; Tamagnone L; Giordano S; Bardelli A; Comoglio PM
Oncogene; 1999 Sep; 18(37):5221-31. PubMed ID: 10498872
[TBL] [Abstract][Full Text] [Related]
14. [A simple view on lung cancer biology: the MET pathway].
Ruppert AM; Beau-Faller M; Belmont L; Lavolé A; Gounant V; Cadranel J; Wislez M
Rev Mal Respir; 2011 Dec; 28(10):1241-9. PubMed ID: 22152933
[TBL] [Abstract][Full Text] [Related]
15. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
Koeppen H; Rost S; Yauch RL
J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
[TBL] [Abstract][Full Text] [Related]
16. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions.
Matsumoto K; Nakamura T
Int J Cancer; 2006 Aug; 119(3):477-83. PubMed ID: 16453287
[TBL] [Abstract][Full Text] [Related]
18. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
Parikh PK; Ghate MD
Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
[TBL] [Abstract][Full Text] [Related]
20. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
